Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of 99mTc-glucarate in Chest Pain Patients Suspected With ACS With no Obvious Signs of AMI and With Known Previous CAD.

NCT00614354 is registered in ClinicalTrials.gov with Molecular Targeting Technologies, Inc. as lead sponsor.

NCT NCT00614354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00614354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of 99mTc-glucarate in Chest Pain Patients Suspected With ACS With no Obvious Signs of AMI and With Known Previous CAD.
Lead sponsor
Molecular Targeting Technologies, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2008
Completion date
September 30, 2010
Enrollment
66 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome